Outcomes24

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

21 to 24 of 24

Type	Outcome	Time frame	Population	Units	Measured as
SECONDARY	Phase 2: PFS Per mRECIST v1.1	up to approximately 44.7 months	Phase 2 FAS. Median survival time was estimated using the Kaplan-Meier method. The confidence interval for median survival time was calculated using the method of Brookmeyer and Crowley.	Days	MEDIAN
SECONDARY	Phase 1: Overall Survival	up to approximately 44.7 months	Phase 1 FAS. Median survival time was estimated using the Kaplan-Meier method. The confidence interval for median survival time was calculated using the method of Brookmeyer and Crowley.	Days	MEDIAN
SECONDARY	Phase 2: Overall Survival	up to approximately 44.7 months	Phase 2 FAS. Median survival time was estimated using the Kaplan-Meier method. The confidence interval for median survival time was calculated using the method of Brookmeyer and Crowley.	Days	MEDIAN
SECONDARY	Phase 2: : Number of Participants With Any TEAE	up to approximately 27.4 months	Phase 2 FAS	Participants	COUNT_OF_PARTICIPANTS

Source ClinicalTrials.govtrials-2026-11-12-0.4.0

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNone stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT03126110/outcomes?page=2